BAY-3827 NEW
| Price | $51 | $122 | $197 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-09 |
Product Details
| Product Name: BAY-3827 | CAS No.: 2377576-35-5 |
| Purity: 99.90% | Supply Ability: 10g |
| Release date: 2025/11/09 |
Product Introduction
Bioactivity
| Name | BAY-3827 |
| Description | BAY-3827 is a potent and selective AMPK inhibitor with potential antitumor activity, demonstrating antiproliferative effects in an androgen-dependent prostate cancer model and inhibiting the phosphorylation of acetyl CoA carboxylase 1 (ACC-1). |
| In vitro | BAY-3827, in the concentration range of 0-200 μM, inhibits AMPK kinase activity with IC50 values of 1.4 nM at low ATP concentration (10 µM) and 15 nM at high ATP concentration (2 mM)[1].In the concentration range of 0-200 μM, BAY-3827 inhibits Aurora A, Flt3, c-Met, and Rsk4 with IC50 values of 1324, 124, 788, and 36 nM, respectively, at 10 µM ATP concentration[1].After overnight treatment, BAY-3827 strongly reduces ACC1 Ser79 phosphorylation in LNCaP and VCaP cells, with a lesser extent in IMR-32 and especially in Colo320 cells[1].At concentrations of 0-10 nM over 6 days, BAY-3827 exhibits strong inhibitory effects on LNCaP and VCaP cells[1].At concentrations of 1 and 5 μM over 24 and 48 hours, BAY-3827 represses LIPE gene expression, reduces serine/threonine kinase AKT3, and blocks the expression of several genes from the mitochondrial carnitine palmitoyltransferase (CPT) family, which is involved in acyl carnitine formation in VCaP cells[1]. At a concentration of 5 μM over 2-4 days, BAY-3827 significantly increases the formation of lipid droplets compared to androgen treatment only[1]. |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 20 mg/mL (42.69 mM), Sonication is recommended. |
| Keywords | AMPK | acyl-CoA oxidase-1 |
| Inhibitors Related | Doxorubicin hydrochloride | RGX-202 | Adenosine monophosphate | Cyclandelate | Adenosine 5'-monophosphate monohydrate | Metformin | Methyl cinnamate | 2-Furoic acid | Metformin hydrochloride | Chitosan oligosaccharide | Buformin hydrochloride | HTH-01-015 |
| Related Compound Libraries | Glycometabolism Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Autophagy Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $2500.00/100mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $4400.00/100mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY